Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-5670a + DS-5670b
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DS-5670a + DS-5670b is a bivalent mRNA-based vaccine developed by Daiichi Sankyo for the prevention of COVID-19, specifically designed for use as a booster dose. Unlike other prominent mRNA vaccines that utilize the full-length spike protein, this vaccine platform focuses on the receptor-binding domain (RBD) of the spike protein, which is the primary target for neutralizing antibodies. The bivalent formulation consists of two mRNA components: DS-5670a, which targets the original (ancestral) SARS-CoV-2 strain, and DS-5670b, which targets the Omicron BA.4/5 variants. The mRNA is encapsulated in a proprietary lipid nanoparticle (LNP) delivery system developed by Daiichi Sankyo. In November 2023, it became the first domestically developed mRNA vaccine to receive approval in Japan for use as a booster, following the earlier approval of the monovalent version.
- Brand names
- Daichirona
- Other names
- DS-5670 (bivalent)Daichirona for BoosterDaiichi Sankyo bivalent mRNA vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on DS-5670a + DS-5670b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-5670a + DS-5670b.